The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Doxorubicin: nanotechnological overviews from bench to bedside
Open accessAbstract
Doxorubicin (DOX) is considered one of the most effective chemotherapeutic agents, used as a first-line drug in numerous types of cancer. Nevertheless, it exhibits serious adverse effects, such as lethal cardiotoxicity and dose-limiting myelosuppression. In this review, we focus on the description and the clinical benefits of different DOX-loaded nanotechnological platforms, not only those commercially available but also the ones that are currently in clinical phases, such as liposomes, polymeric nanoparticles, polymer-drug conjugates, polymeric micelles and ligand-based DOX-loaded nanoformulations. Although some DOX-based nanoproducts are currently being used in the clinical field, it is clear that further research is necessary to achieve improvements in cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Liposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Gewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910
Structure and design of polymeric surfactant-based drug delivery systems
Torchilin, V. P. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00299-1 · Cited by 1,822
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Doxorubicin pathways: pharmacodynamics and adverse effects
Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833ffb56 · Cited by 1,648
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Pharmacokinetics and Biodistribution of Nanoparticles
Li, S.-D., & Huang, L. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800049w · Cited by 1,568
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,561
Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984) · Science · doi:10.1126/science.6093249 · Cited by 1,538
Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation
Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Prasad, S. V. N., Mutharasan, R. K., Naik, T. J., & Ardehali, H. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72931 · Cited by 878
Progress of drug-loaded polymeric micelles into clinical studies
Cabral, H., & Kataoka, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.042 · Cited by 837
Role of nanotechnology in targeted drug delivery and imaging: a concise review
Koo, O. M., Rubinstein, I., & Onyuksel, H. (2005) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2005.06.004 · Cited by 718
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689
Mulier, S., Ni, Y., Jamart, J., Ruers, T., Marchal, G., & Michel, L. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000171032.99149.fe · Cited by 688
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Fendler, J. H., & Romero, A. (1977) · Life Sciences · doi:10.1016/0024-3205(77)90481-7 · Cited by 657
Northfelt, D. W., Dezube, B. J., Thommes, J. A., Miller, B. J., Fischl, M. A., Friedman-Kien, A., Kaplan, L. D., Du Mond, C., Mamelok, R. D., & Henry, D. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2445 · Cited by 649
Enzymes inside lipid vesicles: preparation, reactivity and applications
Walde, P., & Ichikawa, S. (2001) · Biomolecular Engineering · doi:10.1016/s1389-0344(01)00088-0 · Cited by 635
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
Adriamycin, 14‐hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius
Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C., & Spalla, C. (1969) · Biotechnology and Bioengineering · doi:10.1002/bit.260110607 · Cited by 622
Development of the polymer micelle carrier system for doxorubicin
Nakanishi, T., Fukushima, S., Okamoto, K., Suzuki, M., Matsumura, Y., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00341-8 · Cited by 570
Functionalized micellar systems for cancer targeted drug delivery
Sutton, D., Nasongkla, N., Blanco, E., & Gao, J. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9223-y · Cited by 557
Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., & TLC D‐99 Study Group (2002) · Cancer · doi:10.1002/cncr.10201 · Cited by 512
Polymeric Micelles for Delivery of Poorly Water-Soluble Compounds
Kwon, G. S. (2003) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v20.i5.20 · Cited by 502
Tan, C., Tasaka, H., Yu, K.-P., Murphy, M. L., & Karnofsky, D. A. (1967) · Cancer · doi:10.1002/1097-0142(1967)20:3<333::aid-cncr2820200302>3.0.co;2-k · Cited by 486
PEG-based micelles as carriers of contrast agents for different imaging modalities
Torchilin, V. P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00019-4 · Cited by 470
Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
Seymour, L. W., Ferry, D. R., Anderson, D., Hesslewood, S., Julyan, P. J., Poyner, R., Doran, J., Young, A., Burtles, S. S., & Kerr, D. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1668 · Cited by 435
Solitary Colorectal Liver Metastasis: Resection Determines Outcome
Aloia, T. A. (2006) · Archives of Surgery · doi:10.1001/archsurg.141.5.460 · Cited by 432
Szebeni, J., Muggia, F., Gabizon, A., & Barenholz, Y. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.017 · Cited by 423
Gordon, A. N., Tonda, M., Sun, S., & Rackoff, W. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.07.011 · Cited by 422
Martins, S., Sarmento, B. F. C. C., Ferreira, D., & Souto, E. B. (2007) · PubMed Central · Cited by 399
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382
Stewart, S., Jablonowski, H., Goebel, F. D., Arasteh, K., Spittle, M., Rios, A., Aboulafia, D., Galleshaw, J., & Dezube, B. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.683 · Cited by 358
The Liposomal Formulation of Doxorubicin
Abraham, S. A., Waterhouse, D. N., Mayer, L. D., Cullis, P. R., Madden, T. D., & Bally, M. B. (2005) · Methods in Enzymology · doi:10.1016/s0076-6879(05)91004-5 · Cited by 355
A complementary definition of nanomaterial
Kreyling, W. G., Semmler-Behnke, M., & Chaudhry, Q. (2010) · Nano Today · doi:10.1016/j.nantod.2010.03.004 · Cited by 334
Mohan, P., & Rapoport, N. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100269f · Cited by 331
Anticancer Polymeric Nanomedicines
Tong, R., & Cheng, J. (2007) · Polymer Reviews · doi:10.1080/15583720701455079 · Cited by 310
Seymour (2009) · International Journal of Oncology · doi:10.3892/ijo_00000293 · Cited by 304
Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9399-1 · Cited by 303
Greene, R. F., Collins, J. M., Jenkins, J., Speyer, J. L., & Myers, C. E. (1983) · PubMed · Cited by 292
Doroshow, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4514 · Cited by 269
Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.
Rahman, A. M., Yusuf, S. W., & Ewer, M. S. (2007) · PubMed Central · Cited by 267
Nanoparticle Aggregation: Principles and Modeling
Zhang, W. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-017-8739-0_2 · Cited by 264
Leonard, R. C. F., Williams, S., Tulpule, A., Levine, A. M., & Oliveros, S. (2009) · The Breast · doi:10.1016/j.breast.2009.05.004 · Cited by 257
Therapeutic Nanoparticles in Clinics and Under Clinical Evaluation
Schütz, C. A., Juillerat-Jeanneret, L., Mueller, H., Lynch, I., & Riediker, M. (2013) · Nanomedicine · doi:10.2217/nnm.13.8 · Cited by 242
Liposomes: Applications in Medicine
Banerjee, R. (2001) · Journal of Biomaterials Applications · doi:10.1106/ra7u-1v9c-rv7c-8qxl · Cited by 211
Development of liposomal formulations: From concept to clinical investigations
Fan, Y., & Zhang, Q. (2013) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2013.07.010 · Cited by 206
Recent advances in liposomal drug-delivery systems
Chonn, A., & Cullis, P. R. (1995) · Current Opinion in Biotechnology · doi:10.1016/0958-1669(95)80115-4 · Cited by 200
Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin
Solomon, R., & Gabizon, A. A. (2008) · Clinical Lymphoma and Myeloma · doi:10.3816/clm.2008.n.001 · Cited by 199
New signal transduction paradigms in anthracycline-induced cardiotoxicity
Ghigo, A., Li, M., & Hirsch, E. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.01.021 · Cited by 194
Poon, R. T., & Borys, N. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802677874 · Cited by 189
Julyan, P. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00124-2 · Cited by 180
Nanocarriers for intravenous injection—The long hard road to the market
Wacker, M. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.08.079 · Cited by 170
Clinical Developments in Nanotechnology for Cancer Therapy
Heidel, J. D., & Davis, M. E. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0178-7 · Cited by 170
Chan, S. Y. T., Davidson, N. G. P., Juozaitytė, E., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh393 · Cited by 155
Drug targeting with nanoparticles
Kreuter, J. (1994) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03188928 · Cited by 153
Use of liposomal anthracyclines in Kaposi’s sarcoma
Krown, S. E., Northfelt, D., Osoba, D., & Stewart, J. S. W. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.08.003 · Cited by 150
Rifkin, R. M., Gregory, S. A., Mohrbacher, A. M., & Hussein, M. A. (2006) · Cancer · doi:10.1002/cncr.21662 · Cited by 130
Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics
Marchal, S., Hor, A. E., Millard, M., Gillon, V., & Bezdetnaya, L. (2015) · Drugs · doi:10.1007/s40265-015-0453-3 · Cited by 117
Liposomes preparation methods.
Riaz, M. (1996) · PubMed · Cited by 113
Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects
Alphandéry, E., Grand-Dewyse, P., Lefèvre, R., Mandawala, C., & Durand‐Dubief, M. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1086647 · Cited by 110
Role of pegylated liposomal doxorubicin in ovarian cancer
Thigpen, J. T., Aghajanian, C. A., Alberts, D. S., Campos, S. M., Gordon, A. N., Markman, M. M., McMeekin, D. S., Monk, B. J., & Rose, P. G. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.09.046 · Cited by 102
Schilt, Y., Berman, T., Wei, X., Barenholz, Y., & Raviv, U. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.09.012 · Cited by 93
Robert, J., Vrignaud, P., Nguyen-Ngoc, T., Iliadis, A., Mauriac, L., & Hurteloup, P. (1985) · PubMed · Cited by 90
Natural glycoconjugates with antitumor activity
Ferla, B. L., Airoldi, C., Zona, C., Orsato, A., Cardona, F., Merlo, S., Sironi, E., D’Orazio, G., & Nicotra, F. (2010) · Natural Product Reports · doi:10.1039/c0np00055h · Cited by 87
Hong, R., & Tseng, Y. (2001) · Cancer · doi:10.1002/1097-0142(20010501)91:9<1826::aid-cncr1203>3.0.co;2-j · Cited by 84
Fang, X., Zhang, J., Xie, X., Liu, D., He, C., Wan, J., & Chen, M. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.01.029 · Cited by 83
Scotti, C., & Hutchinson, C. R. (1996) · Journal of Bacteriology · doi:10.1128/jb.178.24.7316-7321.1996 · Cited by 80
A review of nanotechnological approaches for the prophylaxis of HIV/AIDS
Date, A. A., & Destache, C. J. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.05.012 · Cited by 76
Anthracycline antitumour agents
BOUMA, J., Beijnen, J. H., Bult, A., & UNDERBERG, W. J. M. (1986) · Pharmacy World & Science · doi:10.1007/bf02086146 · Cited by 75
Swenson, C. E., Haemmerich, D., Maul, D. H., Knox, B., Ehrhart, N. P., & Reed, R. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139752 · Cited by 75
Parajuli, N., Hung, T. V., Ishida, K., et al. (2005) · Research in Microbiology · doi:10.1016/j.resmic.2005.03.005 · Cited by 52
Fiallo, M. M. L., Haj-Tayeb, H. B., Suarato, A., & Garnier‐Suillerot, A. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js970436l · Cited by 50
Rau, K.-M., Lin, Y., Chen, Y.-Y., Chen, J., Lee, K., Wang, C., & Chang, H. (2015) · BMC Cancer · doi:10.1186/s12885-015-1433-4 · Cited by 49
How Fe3+ binds anthracycline antitumour compounds
Fiallo, M. M. L., Garnier‐Suillerot, A., Matzanke, B. F., & Kozłowski, H. (1999) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(99)00040-9 · Cited by 45
A tale of the two PEGylated liposomal doxorubicins
Liu, H., Chou, H., & Lin, H. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s79089 · Cited by 36
Zhang, Z., Sun, Q., Zhong, J.-L., Yang, Q., Li, H., Cheng, D., Liang, B.-L., & Shuai, X. (2013) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.1729 · Cited by 33
Complement Activation, Immunogenicity, and Immune Suppression as Potential Side Effects of Liposomes
Szebeni, J., & Barenholz, Y. (2020) · doi:10.1201/9781003125259-12 · Cited by 24
Intravenous Medications: A Handbook for Nurses and Allied Health Professionals
GAHART, B. L., & NAZARENO, A. R. (1981) · Cited by 22
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Nie, Y., Li, D., Peng, Y., Wang, S., Hu, S., Liu, M., Ding, J., & Zhou, W. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119513 · Cited by 495
Paclitaxel: What has been done and the challenges remain ahead
Bernabeu, E., Cagel, M., Lagomarsino, E., Moretton, M., & Chiappetta, D. A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.016 · Cited by 413
Self-citationNorouzi, M., Yathindranath, V., Thliveris, J. A., Kopec, B. M., Siahaan, T. J., & Miller, D. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-68017-y · Cited by 292
Evolution and clinical translation of drug delivery nanomaterials
Hassan, S., Prakash, G., Bal Ozturk, A., Saghazadeh, S., Farhan Sohail, M., Seo, J., Remzi Dokmeci, M., Zhang, Y. S., & Khademhosseini, A. (2017) · Nano Today · doi:10.1016/j.nantod.2017.06.008 · Cited by 288
Metadata
- Authors
- Cagel, M., Grotz, E., Bernabeu, E., Moretton, M. A., & Chiappetta, D. A.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 22
- Issue
- 2
- Pages
- 270-281
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2555627105
- Cited by
- 362
- References
- 83
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.